NCT02102932View on ClinicalTrials.gov

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy
Interventions
DRUG

5 mg empagliflozin/850 mg metformin FDC

5 mg empagliflozin/850 mg metformin FDC

DRUG

12.5 mg empagliflozin

10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet

DRUG

12.5 mg empagliflozin

10mg empagliflozin tablet and 2.5 mg empagliflozin tablet

DRUG

850 mg metformin

850mg metformin tablet

DRUG

5 mg empagliflozin

5 mg empagliflozin

DRUG

5 mg empagliflozin

5 mg empagliflozin

DRUG

850 mg metformin

850 mg metformin

DRUG

12.5 mg empagliflozin/850 mg metformin FDC

12.5 mg empagliflozin/850 mg metformin FDC

DRUG

12.5 mg empagliflozin/500 mg metformin FDC

12.5 mg empagliflozin/500 mg metformin FDC

DRUG

5 mg empagliflozin/500 mg metformin FDC

5 mg empagliflozin/500 mg metformin FDC

DRUG

500 mg metformin

500 mg metformin

DRUG

500 mg metformin

500 mg metformin

Trial Locations (1)

Unknown

1276.23.86002 Boehringer Ingelheim Investigational Site, Beijing

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY